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Abstract
Alcohol consumption has been associated with a
decreased risk for renal cell cancer in several studies.
We investigated whether alcohol is associated with
(epi)genetic changes of the von Hippel–Lindau (VHL)
gene in renal cell cancer. The Netherlands Cohort
Study (NLCS) on Diet and Cancer started in 1986 (n =
120,852) and uses the case-cohort method. After 11.3
years of follow-up, 314 renal cell cancer cases and 4,511
subcohort members were available for analysis. DNA
was isolated from paraffin-embedded tumor tissue
from 235 cases. VHL mutations were analyzed by
sequencing, whereas VHL promoter methylation was
analyzed using methylation-specific PCR. In multivar-
iate analysis, hazard ratios of renal cell cancer for
cohort members who consumed up to 5, 15, 30, and z30
g of alcohol per day were 0.72, 0.64, 0.81, and 0.69,
respectively, compared with nondrinkers [95% confi-
dence interval (95% CI) for the z30 category, 0.44-1.07;
P for trend, 0.17]. Alcohol intake from beer, wine, and
liquor was associated with decreased risks for renal cell
cancer, although not statistically significant. Hazard
ratios were not different for clear-cell renal cell cancer
with and without VHL mutations, except for alcohol
from beer, which was associated with an increased risk
for clear-cell renal cell cancer without VHL mutations
(hazard ratio for z5 g of alcohol from beer compared
with nondrinkers, 2.74; 95% CI, 1.35-5.57). Alcohol was
associated with a decreased risk for clear-cell renal cell
cancer without VHL gene promoter methylation (haz-
ard ratio for >15 g compared with nondrinkers, 0.58;
95% CI, 0.34-0.99). In this study, a not statistically
significant inverse association was observed between
alcohol and renal cell cancer. There was no statistical
significant heterogeneity by VHL mutation or methyl-
ation status. (Cancer Epidemiol Biomarkers Prev
2008;17(12):3543–50)
Introduction
In a recent pooled analysis of 12 prospective cohort
studies, alcohol consumption was associated with a
decreased risk for renal cell cancer (1). Persons who
drank >15 g of alcohol per day had a decreased risk by
28% compared with nondrinkers. However, this pooled
analysis could not investigate whether the association
was different for the different histologic subtypes of renal
cell cancer because histology was not specified for most
cases (1).
Renal cell cancer is classified in different subtypes.
Most renal cell cancers are of the clear-cell type (f80%);
other subtypes are papillary renal cell cancer (10%),
chromophobe renal cell cancer (5%), collecting-duct
carcinoma (1%), and unclassified renal cell cancer
(3-5%; ref. 2). von Hippel–Lindau (VHL) disease is a
rare inherited disorder associated with (among others)
an increased risk for clear-cell renal cell cancer (3). After
the identification of the VHL gene on chromosome 3p25,
it became evident that this gene is also involved in the
development of sporadic clear-cell renal cell cancer. It is
estimated that f75% of all sporadic clear-cell renal cell
cancer harbor biallelic VHL defects (4). Besides muta-
tions, the VHL gene can be inactivated by other
mechanisms like hypermethylation of the VHL gene
promoter region (5). It has been suggested that risk
factors might be associated with mutations in the VHL
gene: occupational exposure to trichloroethylene and
fruit consumption were associated with mutations in the
VHL gene in renal cell cancer (6, 7).
Whether alcohol consumption is associated with clear-
cell renal cell cancer as such or more specifically with
(epi)genetic alterations of the VHL gene has not been
investigated before. Alcohol degrades methyl donors and
has been found to be associated with hypomethylation of
the genome in cancer (8). However, paradoxically, in
cancer the promoter region of tumor suppressor genes
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are often hypermethylated. It has been hypothesized that
the hypermethylation of promoter regions of genes has
been induced by a compensatory up-regulation of DNA
methyltransferase activity (9). In that case, however,
alcohol consumption is not expected to be inversely
associated with hypermethylation of the VHL gene in
renal cell cancer.
We studied whether alcohol consumption is associated
with risk for renal cell cancer and more specifically with
mutational status or promoter hypermethylation of the
VHL gene in clear-cell renal cell cancer within a large
prospective cohort study.
Materials and Methods
Subjects. The NLCS on Diet and Cancer is a
prospective cohort study, which started in September
1986. The study design has been reported in detail
elsewhere (10). Briefly, the cohort included 120,852 men
and women, aged 55 to 69 y, at the beginning of the
study. The study was designed as a case-cohort study,
using all cases and a random sample of 5,000 persons
from the cohort (subcohort), who have been followed to
estimate the accumulated person-years in the entire
cohort (11). The subcohort was sampled randomly from
the cohort after the baseline exposure measurement.
Follow-up for incident cancer has been established by
computerized record linkage with the Netherlands
Cancer Registry and Pathologisch-Anatomisch Landelijk
Geautomatiseerd Archief (PALGA), a national database
of pathology reports. The method of record linkage to
obtain information on cancer incidence has been de-
scribed previously (12). The completeness of cancer
follow-up was estimated to be >96% (13). From 1986 to
1997 (11.3 y follow-up), 355 kidney cancer cases
(International Classification of Diseases for Oncology 3,
C64.9) were identified. Urothelial cell carcinomas were
excluded and only histologically confirmed epithelial
cancers were included (International Classification of
Diseases for Oncology: M8010-8119, 8140-8570), leaving
337 cases. The PALGA database was used to identify the
location of tumor tissue storage in the Dutch pathologic
laboratories. For 273 cases, a PALGA record including
information on the location of paraffin material could be
identified within the PALGA database at the start of the
collection of paraffin blocks. For 251 (92%) of 273 cases,
paraffin blocks were collected. Failure to retrieve
material was the result of the refusal of the pathology
laboratory to cooperate (3 laboratories with material for
10 cases), the unavailability of suitable material (that is,
only material from a biopsy, cytology, or a metastasis
was present; 8 cases), not being able to locate the paraffin
block at the laboratory (3 cases), and for 1 case, the
reason was not recorded.
Material of 16 cases was discarded after revision. The
collected material was unsuitable for analysis because it
concerned a biopsy (n = 2) or a metastasis (n = 2), no
tumor tissue was present (n = 4), or material contained
<10% malignant cells (n = 7; tumor samples had to
contain at least 10% malignant cells to decrease the
possibility of missing mutations). Material from one case
was reclassified as urothelial cell carcinoma. Thus, tumor
DNA from 235 cases was available for further analysis
(235 of 337 or 70% of all kidney cancer cases and 235 of
273 or 86% of the renal cell cancer cases with information
on the location of the paraffin block).
All subcohort members who reported prevalent cancer
(excluding skin cancer) at baseline were excluded from
analyses (leaving 4,774 subcohort members).
Cases and subcohort members with incomplete or
missing information on alcohol consumption were
excluded from analysis, leaving 314 cases and 4,511
subcohort members available for analysis (14 cases were
also part of the subcohort). Hazard ratios for renal cell
cancer were calculated for intake of alcohol.
Case groups were defined as follows: total renal cell
cancer, all histologically confirmed cases of renal cell
cancer detected by linkage to cancer and pathology
registries (n = 314); clear-cell renal cell cancer, tumor
block collected and classified as clear-cell renal cell
cancer after pathologic revision (n = 176); mutated clear-
cell renal cell cancer, clear-cell renal cell cancer with a
mutation in the VHL gene (n = 106), wildtype clear-cell
renal cell cancer, clear-cell renal cell cancer without a
mutation in the VHL gene (n = 70); methylated clear-cell
renal cell cancer, clear-cell renal cell cancer with a
methylated VHL promoter (n = 14); and unmethylated
clear-cell renal cell cancer, clear-cell renal cell cancer
without a methylated VHL promoter (n = 124).
Questionnaire. At baseline, cohort members complet-
ed a self-administered questionnaire on risk factors for
cancer. The food-frequency section concentrated on
habitual consumption during the preceding year. Con-
sumption of alcoholic beverages was addressed by
questions on beer, red wine, white wine, sherry, other
fortified wines, liqueur, and liquor. The questionnaire
data of all cases and subcohortmemberswere key-entered
twice and processed in a manner blinded with respect to
case or subcohort status to minimize observer bias in the
coding and interpretation of data. The questionnaire has
been validated against a 9-d diet record (14). The Pearson
r between the mean daily ethanol intake assessed by the
questionnaire and that estimated by the 9-d record was
0.86 for all subjects and 0.78 for users of alcoholic
beverages (14). Respondents who took alcoholic bever-
ages less than once amonthwere considered nondrinkers.
Four items from the questionnaire (that is, redwine, white
wine, sherry, and liqueur) were combined into one wine
variable because these items were substantially correlat-
ed. Mean daily alcohol consumption was calculated using
theDutch food composition table (15). On the basis of pilot
study data, standard glass sizes were defined as 200 mL
for beer, 105 mL for wine, 80 mL for sherry, and 45 mL for
both liqueur and liquor, corresponding to 8, 10, 11, 7, and
13 g of alcohol, respectively.
VHL Analysis. Paraffin blocks of tumors were
collected from 51 pathology laboratories; the procedures
have been described in detail elsewhere (16). We were
able to collect material for 251 cases. One experienced
pathologist (C.A. Hulsbergen–van de Kaa) revised all
HE-stained slides according to the WHO Classification of
Tumours of 2002 (17). The protocols for DNA isolation
and mutation analyses have been described previously
(16). Briefly, paraffin was removed with xylene, and
tumor DNA was extracted by salt precipitation.
The entire gene was amplified using six primer sets
as described before (16). Samples were first subjected
to PCR–single-strand conformational polymorphism
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analysis, which was followed by direct sequencing in
case of aberrant or unclear results. Separate PCRs were
set up for single-strand conformational polymorphism
and sequencing to reduce the risk for false-positive
results. Mutations were identified by visual inspection of
sequences provided by the ABI basecaller. After revision
and VHL gene mutation analyses, data were available for
235 cases (16).
DNA methylation in the CpG island of the VHL gene
promoter was determined by chemical modification of
genomic DNA with sodium bisulfite and subsequent
methylation-specific PCR analysis as described in detail
elsewhere (18). In brief, 500 ng of DNA was denatured by
NaOH and modified by sodium bisulfite. DNA samples
were then purified using Wizard DNA purification resin
(Promega), again treated with NaOH, precipitated with
ethanol, and resuspended in H2O. To enable methyla-
tion-specific PCR analysis on formalin-fixed, paraffin-
embedded tissue, VHL methylation-specific PCR primers
as described in ref. 18 and designed in a region of the
promoter CpG island, of which methylation has been
associated with inhibition of VHL gene expression, were
adapted for nested methylation-specific PCR analysis.
Primers are available upon request. VHL methylation-
specific PCR reproducibility was 93% (37 of 40 duplicate
methylation-specific PCRs).
Data Analysis. Confounders considered for multivar-
iable analysis were age at baseline (years), sex, cigarette
smoking (never, former, or current), body mass index
(BMI; kg/m2), energy intake (kcal/d), kidney cancer in
first degree family (yes or no), a diagnosis of diabetes
mellitus (yes or no), a history of hypertension (yes or no),
educational level (four categories: primary school, junior
high school, senior high school, higher vocational school,
or university), and nonoccupational physical activity
(four categories). Those variables that were associated
with alcohol consumption, that were an independent risk
factor of renal cell cancer, and that changed the risk
estimates for the association of alcohol consumption and
renal cell cancer by >10% were included as confounders
in multivariable analyses. Using these criteria, confound-
ers entered in the analyses were age, sex, and cigarette
smoking.
Hazard ratios and corresponding 95% confidence
intervals (95% CI) for renal cell cancer were estimated
using Cox proportional hazard models processed with
the STATA statistical software package (release 9.1, 2005,
STATA Corporation) after testing the proportional
hazards assumption using scaled Schoenfeld residuals
(19). SEs were estimated using the robust Huber-White
sandwich estimator to account for additional variance
introduced by sampling person-time from the cohort
(20). To obtain P values for dose-response trends, ordinal
exposure variables were fitted as continuous terms.
Tests for heterogeneity were done to evaluate differ-
ences between subtypes of tumors (e.g., VHL mutated
versus VHL wildtype) using the competing risks proce-
dure in STATA. However, the SE for the difference of the
log–hazard ratios from this procedure assumes indepen-
dence of both estimated hazard ratios, which would
Table 1. Description of exposure variables and potential confounders in subcohort members, renal cell cancer
cases, and renal cell cancer cases with tissue blocks collected according to sex; NLCS, 1986 to 1997
Males [mean (SD)] Females [mean (SD)]
Subcohort
members
(n = 2,273)
RCC cases
(n = 211)
RCC cases
with collected
tumor material
(n = 145)
Subcohort
members
(n = 2,238)
RCC cases
(n = 103)
RCC cases
with collected
tumor material
(n = 74)
Alcohol intake
Total alcohol intake
Drinkers of alcohol* 1,944 (85.5%) 178 (84.4%) 123 (84.8%) 1,507 (67.3%) 56 (54.4%) 42 (56.8%)
Alcohol intake (g/d)
c
17.5 (16.9) 16.9 (15.5) 16.0 (15.3) 8.6 (10.4) 10.9 (12.6) 8.7 (10.2)
Alcohol intake from beer
Drinkers of beer* 1,296 (57.0%) 114 (54.0%) 84 (57.9%) 222 (9.9%) 11 (10.7%) 9 (12.2%)
Intake of alcohol from beer (g/d)
c
6.4 (9.9) 5.8 (10.1) 6.0 (10.8) 2.7 (4.5) 2.4 (3.0) 2.2 (3.1)
Alcohol intake from wine
Drinkers of wine* 1,187 (52.2%) 109 (51.7%) 73 (50.3%) 1,423 (63.6%) 53 (51.5%) 40 (54.1%)
Alcohol intake from wine (g/d)
c
7.6 (9.7) 6.4 (8.1) 6.2 (8.8) 7.0 (8.6) 8.0 (9.3) 6.5 (7.9)
Alcohol intake from liquor
Drinkers of liquor* 1,324 (58.3%) 121 (57.4%) 87 (60.0%) 296 (13.2%) 11 (10.7%) 8 (10.8%)
Alcohol intake from liquor (g/d)
c
12.6 (13.4) 13.6 (13.5) 11.6 (12.0) 8.1 (9.9) 14.7 (16.3) 10.7 (13.1)
Potential confounders
Age at baseline 61.4 (4.2) 62.0 (3.8) 62.2 (3.8) 61.4 (4.3) 61.5 (3.9) 61.4 (3.9)
BMI 25.0 (2.6) 25.4 (2.7) 25.4 (2.6) 25.1 (3.5) 25.8 (3.3) 25.8 (3.2)
Current smokers of cigarettes* 829 (36.5%) 89 (42.2%) 57 (39.3%) 483 (21.6%) 25 (24.3%) 17 (23.0%)
Cigarettes/d
c,b 17.1 (10.6) 19.3 (12.8) 19.7 (12.8) 11.5 (8.3) 12.7 (8.1) 12.5 (8.3)
Years of smoking
b
33.8 (11.9) 35.7 (11.7) 35.4 (11.4) 28.0 (12.4) 28.8 (12.3) 27.3 (12.8)
Diagnosis of hypertension: yes* 525 (23.1%) 55 (26.1%) 36 (24.8%) 649 (29.0%) 39 (37.9%) 29 (39.2%)
Diagnosis of diabetes mellitus: yes* 77 (3.4%) 7 (3.3%) 6 (4.1%) 84 (3.8%) 4 (3.9%) 3 (4.1%)
Family history of RCC: yes* 14 (0.6%) 3 (1.4%) 2 (1.4%) 32 (1.4%) 1 (1.0%) 1 (1.4%)
Energy intake (including alcohol) 2,168 (511) 2,122 (483) 2,114 (490) 1,692 (397) 1,654 (395) 1,645 (394)
Abbreviation: RCC, renal cell cancer.
*Number (%).
cAmong drinkers only.
bOnly for ever-smokers.
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underestimate that SE and thus overestimate the
P values for their difference. Therefore, these P values
and the associated confidence intervals were estimated
based on a bootstrapping method that was developed
for the case-cohort design (21). For each bootstrap sample,
X subcohort members were randomly drawn from the
subcohort of X subjects and Y cases from the total of
Y cases outside the subcohort, both with replacement, out
of the data set of X + Y observations. The log–hazard
ratios were obtained from this sample using STATA’s
competing risks procedure and recalculated for each
bootstrap replication. The confidence interval and P
value of the differences in hazard ratio of the subtypes
were then calculated from the replicated statistics using
the accelerated bias corrected method in STATA. Each
bootstrap analysis was based on 1,000 replications.
Results
Among men, the proportion of alcohol drinkers was
approximately equal in the subcohort to that in the renal
cell cancer cases, whereas in women, the proportion of
alcohol drinkers was considerably higher in the sub-
cohort than in the renal cell cancer cases. Average alcohol
intake among consumers was slightly higher in male
subcohort members than in male renal cell cancer cases,
whereas in females, the average alcohol intake was lower
in the subcohort (Table 1). Renal cell cancer cases had a
higher BMI at baseline, were more often current smokers,
and were more often diagnosed with hypertension than
subcohort members. In males, energy intake (including
energy from alcohol) was higher in subcohort members
than in cases.
Table 2. Multivariable adjusted hazard ratios and 95% CIs of renal cell cancer for alcohol consumption; NLCS on
Diet and Cancer, 1986 to 1997
Variable Alcohol consumption
at baseline
Alcohol consumption
at baseline
Alcohol consumption
among stable users*
No. of cases/
person-years
subcohort
Age and sex
adjusted
Multivariable
adjusted
No. of cases/
person-years
subcohort
Multivariable
adjusted
No. of cases/
person-years
subcohort
Multivariable
adjusted
HR 95% CI HR
c
95% CI HR
b
95% CI HR
c
95% CI
Total alcohol intake (g/d)
No alcohol intake 80/11,035 1 Ref 1 Ref 75/10,150 1 Ref 61/8,462 1 Ref
0.1-4.9 74/13,706 0.72 0.52-1.00 0.72 0.51-0.99 69/12,643 0.71 0.50-1.00 47/9,147 0.69 0.46-1.02
5-14.9 64/10,823 0.66 0.47-0.94 0.64 0.46-0.91 61/9,986 0.66 0.46-0.94 40/6,702 0.66 0.43-0.99
15-29.9 63/7,437 0.87 0.61-1.24 0.81 0.57-1.16 59/6,976 0.79 0.54-1.15 38/4,003 0.94 0.60-1.47
z30 33/4,299 0.74 0.48-1.15 0.69 0.44-1.07 27/3,972 0.61 0.38-0.98 17/2,333 0.69 0.39-1.23
P for linear trend 0.34 0.17 0.09 0.40
Alcohol increment
per 10 g
314/47,299 0.98 0.90-1.06 0.96 0.89-1.05 291/43,728 0.94 0.86-1.02 203/30,647 0.98 0.88-1.09
Alcohol from beer (g/d)
No alcohol
from beer
189/31,533 1 Ref 1 Ref 174/29,157 1 Ref 126/21,406 1 Ref
0.1-4.9 81/10,208 0.95 0.70-1.30 0.95 0.69-1.29 77/9,448 0.98 0.71-1.35 50/6,009 1.03 0.70-1.52
5-14.9 36/4,215 0.98 0.65-1.46 0.96 0.64-1.43 32/3,912 0.93 0.61-1.43 23/2,433 1.10 0.66-1.83
z15 8/1,344 0.67 0.32-1.41 0.63 0.30-1.33 8/1,209 0.69 0.32-1.45 4/799 0.55 0.19-1.56
P for linear trend 0.46 0.36 0.41 0.69
Alcohol increment
per 10 g
314/47,299 0.92 0.74-1.15 0.91 0.72-1.13 291/43,728 0.92 0.73-1.16 203/30,647 0.83 0.62-1.11
Alcohol from wine (g/d)
No alcohol
from wine
152/19,503 1 Ref 1 Ref 140/17,770 1 Ref 101/13,457 1 Ref
0.1-4.9 97/16,418 0.83 0.63-1.09 0.85 0.64-1.12 90/15,325 0.85 0.64-1.14 64/10,711 0.87 0.62-1.22
5-14.9 46/7,311 0.85 0.60-1.21 0.85 0.60-1.21 44/6,811 0.91 0.64-1.30 27/4,377 0.84 0.53-1.32
z15 19/4,067 0.65 0.40-1.05 0.63 0.38-1.03 17/3,821 0.64 0.38-1.08 11/2,103 0.72 0.38-1.37
P for linear trend 0.06 0.06 0.12 0.23
Alcohol increment
per10 g
314/47,299 0.90 0.76-1.07 0.89 0.75-1.06 291/43,728 0.87 0.73-1.03 203/30,647 0.88 0.69-1.12
Alcohol from liquor (g/d)
No alcohol
from liquor
182/30,543 1 Ref 1 Ref 170/28,057 1 Ref 131/20,708 1 Ref
0.1-4.9 51/7,473 0.84 0.60-1.18 0.84 0.60-1.17 48/7,002 0.80 0.57-1.13 24/4,666 0.60 0.38-0.94
5-14.9 32/4,602 0.80 0.54-1.20 0.78 0.52-1.16 30/4,350 0.73 0.48-1.10 20/2,699 0.79 0.48-1.30
z15 49/4,681 1.17 0.82-1.67 1.10 0.77-1.57 43/4,318 0.98 0.68-1.43 28/2,574 1.11 0.70-1.76
P for linear trend 0.76 0.99 0.55 0.94
Alcohol increment
per 10 g
314/47,299 1.05 0.94-1.17 1.03 0.92-1.15 291/43,728 0.98 0.87-1.11 203/30,647 1.08 0.92-1.26
Abbreviations: HR, hazard ratio; Ref, reference category.
*Participants who reported that they had the same drinking habits at baseline and 5 y before baseline.
cAdjusted for sex, age, and cigarette smoking (never, ex, current). Hazard ratios for alcohol intake from beer, wine, and liquor are mutually adjusted for
intake of alcohol from the other drinks.
bAdjusted for sex, age, and cigarette smoking (never, ex, current), BMI (continuous), and energy intake (continuous, not including energy from alcohol).
Hazard ratios for alcohol intake from beer, wine, and liquor are mutually adjusted for intake of alcohol from the other drinks. Because of missings for BMI
and inconsistent or incomplete dietary information, only 291 cases and 4168 subcohort were available for analysis.
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Multivariable hazard ratios for alcohol intake adjusted
for sex, age, and cigarette smoking were slightly
decreased, although not statistically significant
(Table 2). Cohort members with an alcohol intake of
>30 g/d had a multivariable adjusted hazard ratio of
0.69 (95% CI, 0.44-1.07) compared with cohort members
who did not drink alcohol (P for trend, 0.17). Similar
hazard ratios were observed when BMI and energy intake
were added as covariates to the multivariable model.
Relative risks for men who consumed up to 5, 15, 30, and
>30 g/d were 0.96, 0.84, 0.98, and 0.75, respectively,
compared with nondrinkers (95% CI for the top category,
0.44-1.28). Relative risks for women who consumed up
to 5, 15, 30, and >30 g/d were 0.52, 0.40, 0.68, and 1.08,
respectively, compared with nondrinkers (95% CI for
the top category, 0.44-2.64). The interaction, however, was
not statistically significant (P for interaction, 0.14).
Alcohol intake from beer and wine (each adjusted for
alcohol intake from other sources) were also associated
with nonsignificantly decreased risks, whereas the high-
est alcohol intake group from liquor was not inversely
associated with renal cell cancer risk. The hazard ratios
did not change substantially when analyses were
restricted to subjects who were abstainers or who
reported stable use during 5 years preceding baseline,
although the confidence intervals were wider because of
decreased power (Table 2).
We did not show a difference about hazard ratios for
clear-cell renal cell cancer with and without VHL
mutations (Table 3: P for heterogeneity between sub-
types, 0.53). Some heterogeneity seemed to be present for
alcohol intake from beer, although this was not statisti-
cally significant with a P for heterogeneity of 0.30. We
observed an increased risk for clear-cell renal cell cancer
without VHL mutations, with the hazard ratios for cohort
members who consumed up to 5 and z5 g of alcohol
from beer being 1.71 (95% CI, 0.82-3.56) and 2.74 (95% CI,
1.35-5.57), respectively, compared with nondrinkers of
beer (P for trend, 0.005). Alcohol originating from wine
and liquor was not associated with renal cell cancer risk,
with or without VHL mutations. The prevalence of VHL
promoter hypermethylation was the highest in cases that
reported an alcohol intake of z15 g/d: 20%, compared
with 11.1% and 4.5% in cases that reported no or 0.1 to
14.9 g alcohol per day, respectively. In multivariate
analysis (Table 4), alcohol intake was associated with a
decreased risk for clear-cell renal cell cancer without
hypermethylation of the VHL gene, the hazard ratios for
cohort members who consumed up to 5 and z5 g of
alcohol from beer were 0.81 (95% CI, 0.52-1.25) and 0.58
(95% CI, 0.34-0.99), respectively, compared with non-
drinkers (P for trend, 0.04). Hazard ratios for clear-cell
renal cell cancer with a hypermethylated promoter
region of the VHL gene were mostly greater than one,
although the number of cases was small and the P for
heterogeneity was far from statistically significant.
Discussion
In this study, we observed that alcohol intake was
associated with a decreased risk for renal cell cancer,
although not statistically significant. We did not show a
Table 3. Multivariable adjusted hazard ratios and 95% CIs of renal cell cancer according for alcohol consumption
according to VHL mutational status; NLCS on Diet and Cancer, 1986 to 1997
Variable and level Person-years
subcohort
Clear-cell
carcinoma
Clear-cell
carcinoma,
VHL mutated
Clear-cell carcinoma,
VHL wildtype
P for
heterogeneity
No. of
cases
HR* 95% CI No. of
cases
HR* 95% CI No. of
cases
HR* 95% CI
Total alcohol intake (g/d)
No alcohol intake 11,035 46 1 Ref 28 1 Ref 18 1 Ref
0.1-4.9 13,706 46 0.76 0.50-1.16 27 0.73 0.42-1.25 19 0.82 0.43-1.58
5-14.9 10,823 33 0.59 0.37-0.93 15 0.42 0.22-0.81 18 0.86 0.45-1.64
z15 11,735 51 0.74 0.48-1.14 36 0.83 0.48-1.43 15 0.59 0.29-1.19 0.53
P for linear trend 0.16 0.44 0.16
Alcohol increment per 10 g 47,299 176 0.94 0.83-1.05 106 0.99 0.86-1.14 70 0.83 0.68-1.01 0.049
Alcohol from beer (g/d)
No alcohol from beer 31,533 105 1 Ref 68 1 Ref 37 1 Ref
0.1-4.9 10,208 42 1.00 0.65-1.56 25 0.75 0.44-1.28 17 1.71 0.82-3.56
z5 5,559 29 1.19 0.74-1.91 13 0.67 0.35-1.29 16 2.74 1.35-5.57 0.30
P for linear trend 0.54 0.19 0.005
Alcohol increment per 10 g 47,299 176 1.00 0.77-1.29 106 0.92 0.56-1.49 70 1.09 0.88-1.35 0.69
Alcohol from wine (g/d)
No alcohol from wine 19,503 86 1 Ref 54 1 Ref 32 1 Ref
0.1-4.9 16,418 57 0.85 0.59-1.21 31 0.73 0.46-1.17 26 1.04 0.60-1.79
z5 11,379 33 0.66 0.43-1.00 21 0.67 0.40-1.12 12 0.63 0.31-1.30 0.68
P for linear trend 0.049 0.10 0.25
Alcohol increment per 10 g 47,299 176 0.80 0.60-1.06 106 0.87 0.63-1.20 70 0.67 0.38-1.17 0.49
Alcohol from liquor (g/d)
No alcohol from liquor 30,543 104 1 Ref 62 1 Ref 42 1 Ref
0.1-4.9 7,473 30 0.94 0.61-1.45 14 0.67 0.36-1.24 16 1.43 0.79-2.57
z5 9,283 42 0.96 0.64-1.42 30 1.06 0.65-1.72 12 0.77 0.39-1.53 0.10
P for linear trend 0.81 0.93 0.59
Alcohol increment per 10 g 47,299 176 0.99 0.85-1.16 106 1.09 0.92-1.29 70 0.79 0.57-1.09 0.04
NOTE: Relative risks for alcohol intake from beer, wine, and liquor are mutually adjusted for intake of alcohol from the other drinks.
*Adjusted for sex, age, and cigarette smoking (never, ex, current).
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statistical significant difference in hazard ratios for renal
cell cancer with or without mutations in the VHL gene,
although hazard ratios of alcohol intake from beer were
increased in clear-cell renal cell cancer without mutations
in the VHL gene. Hazard ratios were significantly
decreased in clear-cell renal cell cancer without methyl-
ation of the promoter region of the VHL gene. To our
knowledge, this is the first study investigating the
association between alcohol intake and mutational status
and promoter-region hypermethylation of the VHL gene
in renal cell cancer.
The overall results of this analysis are in agreement
with a recent publication of the Pooling Project of
Prospective Studies on Diet and Cancer, including 12
prospective cohort studies (1). The NLCS was included
in that analysis, as well as most prospective studies
that have published results on this association thus far
(22-27). Three prospective cohort studies were not
included in the analysis of the pooling project (27-29),
two of which (28, 29) did not observe an association
between alcohol intake and renal cell cancer risk, but the
numbers of cases in these studies were rather small
(19 and 44 cases, respectively). The third prospective
cohort study did observe an inverse association (27).
Results among case-control studies are more heteroge-
neous. Most case-control studies observed no association
or a positive association (30-45), whereas some published
a negative association between alcohol intake and renal
cell cancer risk (46-50). The International Renal Cancer
Case-Control study published a statistically significant
negative association in women and no association in men
(51). The discrepancies between case-control and pro-
spective studies may be explained by the fact that case-
control studies are more liable to recall and selection bias.
In our analysis, we observed that the association did
not change when the analysis was restricted to the cohort
members who reported a stable use. This does suggest
that the effect is not limited to the latest phases of renal
cell cancer development. It would have been interesting
to study the subgroups who reported a lower or higher
consumption at baseline than 5 years before, but the
numbers in these subgroups were too small for a
meaningful analysis.
In the current study, it was possible to study the
association with specific subtypes of renal cell cancer
according to histology and (epi)genetic aberrations of the
VHL gene. The results in clear-cell renal cell cancer were
not significantly different from renal cell cancer overall.
Likewise, we did not observe a statistically significant
difference in the association of alcohol intake and clear-
cell carcinoma, with or without mutations in the VHL
gene. Unexpectedly, alcohol consumption from beer was
associated with an increased risk for renal cell cancer
without a VHL mutation. This could indicate an effect of
specific constituents in beer. For example, nitrosamines
have been associated with increased risk for cancer (52)
and was present in large quantities in Dutch beer in the
past (53). Although some studies reported a negative
association between beer intake and renal cell cancer risk
that was weaker than the association between total
alcohol intake and renal cell cancer risk (1, 46), other
studies did not observe a difference (39, 50). In these
studies, only the association with renal cell cancer was
investigated, disregarding histology and VHL mutation
status. It cannot be excluded, however, that this result is
a chance finding because the number of exposed cases
with this specific endpoint is small.
The negative association between alcohol intake and
renal cell cancer risk was strongest and also statistically
significant in the subgroup of clear-cell renal cell cancer
without promoter hypermethylation of the VHL gene. In
the subgroup with promoter hypermethylation, risks
were mostly higher than one, but the number of cases
was very small, hampering more definitive conclusions.
The observed heterogeneity between the subgroups
according to methylation status are, however, in agree-
ment with the theory that alcohol is associated with an
increased risk of hypermethylation of gene promoters
such as the VHL gene (8). In addition, other genes that
may play a role in renal carcinogenesis can be inactivated
by promoter hypermethylation as well, for example,
APAF1, JUP, RASSF1, COL1A1, and TIMP3 (54). Alcohol
consumption may also be associated with hypermethy-
lation of the promoter regions of these and other tumor
suppressor genes and thus promote cancer development
in a specific subgroup of renal cell cancer (those with
Table 4. Multivariable adjusted hazard ratios and 95% CIs of renal cell cancer according for alcohol consumption
according to methylation status of the promoter region of the VHL gene; NLCS on Diet and Cancer, 1986 to 1997
Variable and level Person-years
subcohort
Clear-cell carcinoma,
VHL methylated
Clear-cell carcinoma,
VHL not methylated
P for
heterogeneity
No. of cases HR* 95% CI No. of cases HR* 95% CI
Alcohol intake
No. 11,035 4 1 Ref 32 1 Ref
0.1-14.9 24,529 3 0.28 0.06-1.35 64 0.81 0.52-1.25
z15 11,735 7 1.43 0.31-6.62 28 0.58 0.34-0.99 0.29
P for linear trend 0.53 0.04
Alcohol increment per 10 g 47,299 14 1.08 0.80-1.45 124 0.82 0.70-0.97 0.17
Alcohol intake from beer
Alcohol increment per 10 g 47,299 14 1.12 0.59-2.12 124 0.84 0.62-1.12 0.34
Alcohol intake from wine
Alcohol increment per 10 g 47,299 14 1.30 0.74-2.29 124 0.68 0.45-1.03 0.32
Alcohol intake from liquor
Alcohol increment per 10 g 47,299 14 0.84 0.41-1.72 124 0.90 0.72-1.12 0.09
NOTE: Relative risks for alcohol intake from beer, wine, and liquor are mutually adjusted for intake of alcohol from the other drinks.
*Adjusted for sex, age, and cigarette smoking (never, ex, current).
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hypermethylation of tumor suppressor genes), although
it may be overall associated with a decreased risk for
renal cell cancer.
There are different explanations for the negative
association between alcohol intake and renal cell cancer
risk. Moderate alcohol intake is associated with a lower
risk for diabetes type II and may be associated with
increased insulin sensitivity (55). Hyperinsulinemia is
possibly associated with risk for kidney cancer (56) and
might therefore explain the observed inverse association
between alcohol and risk for cancer. Another possible
mechanism is the diuretic effect of alcohol, which may
decrease the exposure of renal cells to carcinogens because
of dilution and a shorter duration of exposure. In a pooled
analysis of twoUS prospective studies, no associationwas
observed between water intake and risk for renal cell
cancer (22), making this mechanism less likely.
Although tumors with a VHL mutation in our
population were slightly larger than tumors without a
VHL mutation (16), VHL mutational status was not
associated with nuclear grade, tumor-node-metastasis,
stage, or survival (16, 57). In previous analyses, the
association of cigarette smoking, hypertension and use of
antihypertensive medication, and the intake of carote-
noids and vitamins with VHL mutational status in renal
cell cancer has been investigated. Cigarette smoking was
associated with renal cell cancer risk for men but not
specifically with VHL gene mutations, irrespective of sex,
suggesting that smoking may cause renal cell cancer
independent of VHL gene mutations (58). With respect to
hypertension and use of antihypertensive medications,
the association of hypertension was stronger in renal cell
cancer cases with VHL gene mutations, whereas use of
diuretics was associated with renal cell cancer without
VHL gene mutations (59). Results were suggestive of
higher relative risks for wildtype VHL tumors with
a-carotene, h-cryptoxanthin, folate, and supplemental
vitamin C and multivitamin intake (60).
These results from the NLCS are most likely not
affected by selection or information bias. Selection bias is
unlikely, given the high level of follow-up in terms of
cases and subcohort person-years (13). In theory,
selection bias may have occurred in the collection of
tissue samples. For 235 (70%) of the 337 cases, tumor
material could be collected. There was no indication for
bias in the selection of cases with tumor material
according to the risk factors and potential confounders
studied. Information bias is unlikely in our study because
the information with respect to the risk factors was
collected before the diagnosis of renal cell cancer.
Alcohol consumption and information about potential
confounders were self-reported, however, and misclas-
sification of exposure is a potential source of bias. The
questionnaire has been validated against a 9-day diet
record (14), and the correlation with respect to alcohol
consumption was high.
VHL mutations were determined with sequencing
using single-strand conformational polymorphism as a
screening tool. This was considered sensible because, in a
pilot study with 20 cases, we never detected a mutation
by direct sequencing after a negative result on the single-
strand conformational polymorphism (0% false nega-
tives; ref. 16).
In this prospective study, we observed that alcohol
consumption is inversely associated with the risk for
renal carcinoma. There was overall no heterogeneity
with respect to mutation status of the VHL gene, but
alcohol consumption from beer was positively associat-
ed with renal cell cancer with wildtype VHL gene.
Alcohol consumption was negatively associated with
renal cell cancer without hypermethylation of the VHL
gene. Replication of our results in larger data sets is
required. It should also be investigated whether alcohol
consumption is associated with hypermethylation of
other tumor suppressor genes that are involved in renal
carcinogenesis.
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